Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,180.3
6.3 (0.20%)

 

  • STI Straits Times Index
    3,180.3
    6.3 (0.20%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,605.1
    -3.4 (-0.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,706.9
    253.6 (0.89%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,407.8
    -5.1 (-0.15%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,805.6
    266.9 (0.90%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,948.6
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 579.3M
  • Value: 226.8M
  • Rise: 119
  • Fall: 90
  • Unch: 563

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Anchor Resources0.028-0.004
Oceanus^0.042+0.002
Jiutian Chemical0.100-0.002
Sembcorp Marine0.198+0.003
Aspen0.270+0.005
SPH1.820+0.070
Intl Cement0.057+0.001
GCCP0.023+0.002
ThaiBev0.760-0.005
The Place Hldg0.151+0.006

World Indices

World Indices
Name Last Change
Nasdaq 13,850.0 -50.2
HSI 28,740.0 +286.7
HSCEI 10,948.8 +73.9
Jakarta 5,925.3 -23.2
Nikkei 225 29,833.0 +294.3
SSE Comp 3,411.5 -1.4
Shanghai A 3,575.8 -1.5
Shanghai B 244.9 +0.1
KOSPI 3,160.0 +24.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

SURFACE ONCOLOGY INC SURFACE ONCOLOGY INC
Updated on 12 Apr 2021 (End of trading day)
Last (USD): 7.230 Change: -0.720 High: 7.929 Remarks: -
Change (%): -9.06 Low: 7.140
Open 7.850 Yesterday's Close 7.95
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,572,007 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.42201 Trailing EPS (USD) e 1.42201 NAV (USD) b 3.7325
PE a 5.084 Trailing PE f 5.084 Price / NAV b 1.9370
Dividend (USD) d - Cash In Hand (USD) g 4.1972 Issued & Paid-up Shares c 41,727,700
Dividend Yield (%) d - Price / Cash In Hand g 1.723 Treasury Shares h -
Market Cap (M) 301.691 Enterprise Value (M) 175.819
Piotroski F Score 5 Exchange Code SURF Par Value ( $ ) n.a.
52 Weeks Volatility (%) 101.99 Free Float (%) 79.4
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 10 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Apr 2018.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference SURFACE ONCOLOGY INC NASDAQ 301.691 5.084 5.084 1.9370 -
Industry Biotechnology NASDAQ 2,873.159 106.306 106.381 6.6482 0.615
Local Peer AMGEN INC NASDAQ 143,340.150 19.733 19.733 15.2344 2.582
Local Peer GILEAD SCIENCES INC NASDAQ 81,251.756 660.605 660.583 4.4639 4.198
Local Peer ILLUMINA INC NASDAQ 58,212.641 88.739 88.739 12.4015 -
Local Peer MODERNA INC NASDAQ 55,785.092 - - 21.7792 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 55,527.456 20.477 20.477 6.3921 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 50,651.995 14.418 14.418 4.5942 -
Local Peer BIOGEN INC NASDAQ 40,033.901 10.007 10.007 3.7414 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 33,858.790 56.113 56.113 2.9060 -
Local Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 29,349.632 1,694.131 1,694.030 17.4854 -
Local Peer BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS NASDAQ 27,036.265 - - 6.9875 -
Local Peer SEAGEN INC NASDAQ 25,513.380 41.575 41.575 7.3144 -
Local Peer EXACT SCIENCES CORP NASDAQ 21,126.479 - - 7.4824 -
Other Local Peers 10X GENOMICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), NOVAVAX INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EXELIXIS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SEER INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ARVINAS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), INSTIL BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), MACROGENICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CYTOKINETICS INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), BIOATLA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ALLOVIR INC (NASDAQ), IMMUNOGEN INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), PRECIGEN INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ALECTOR INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AFFIMED N V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), NKARTA INC (NASDAQ), CURIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), VAXCYTE INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), HUMANIGEN INC (NASDAQ), PERSONALIS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), MERUS B V (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), INHIBRX INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), IMMATICS N V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), CHIMERIX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VAXART INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KADMON HLDGS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AGENUS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), AKOUOS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VERASTEM INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), ATRECA INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SESEN BIO INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ADICET BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), LAVA THERAPEUTICS NV (NASDAQ), ATHERSYS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), ONCORUS INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMMUNOME INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), KAMADA LTD (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEXTCURE INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOVIE INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), EQUILLIUM INC (NASDAQ), IMV INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), EVOGENE LTD (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), CHIASMA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), GAIN THERAPEUTICS INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), METACRINE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SYNLOGIC INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ORGENESIS INC (NASDAQ), LONGEVERON INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), OTONOMY INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), LUMOS PHARMA INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), AIKIDO PHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ATYR PHARMA INC (NASDAQ), BIOCARDIA INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), HISTOGEN INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), PRECIPIO INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), GEOVAX LABS INC (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ)
Global Peer CSL LTD ASX 120,834.360 38.528 31.750 11.4347 1.105
Global Peer WUXI BIO HKEx 427,607.571 225.316 225.319 17.5379 -
Global Peer BEIGENE HKEx 214,581.600 - - 7.1524 -
Global Peer SINO BIOPHARM HKEx 150,886.941 48.456 48.457 7.5990 -
Global Peer ZAI LAB-SB HKEx 88,640.369 - - 9.7762 -
Global Peer JOINN HKEx 36,885.766 104.203 104.203 25.3981 0.242
Global Peer Lonza SGX 5,940.891 4.560 4.560 0.5844 5.624
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 4,043.338 13.253 13.253 2.7943 -
Global Peer GENSCRIPT BIO HKEx 29,916.919 - - 4.2789 -
Global Peer 3SBIO HKEx 18,313.920 19.500 19.500 1.4450 -
Other Global Peers ARCUS BIOSCIENCES INC (NYSE), NUVATION BIO INC (NYSE), VIVA BIOTECH (HKEx), JW THERAP-B (HKEx), MYOVANT SCIENCES LTD (NYSE), JACOBIO-B (HKEx), KINTOR PHARMA-B (HKEx), POLYNOVO LIMITED (ASX), HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), FRONTAGE (HKEx), MESOBLAST LTD (ASX), ASCENTAGE-B (HKEx), JHBP-B (HKEx), TELIX PHARMACEUTIC (ASX), IMUGENE LIMITED (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), SINOMAB BIO-B (HKEx), DPHARMA (Bursa), LEE'S PHARM (HKEx), OPTHEA LIMITED (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), SQZ BIOTECHNOLOGIES CO (NYSE), 22ND CENTURY GROUP INC (NYSE American), ANTEOTECH LIMITED (ASX), NANOVIRICIDES INC (NYSE American), IMMUTEP LTD (ASX), NEXT SCIENCE LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), BIOMX INC (NYSE American), CEL-SCI CORP (NYSE American), BIONOMICS LTD (ASX), IBIO INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), LEAF RESOURCES LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), UNI-BIO GROUP (HKEx), CHIMERIC THERAPEUTICS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), REGENT PACIFIC (HKEx), ACTINOGEN MEDICAL LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), CT ENTERPRISE (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), ORAGENICS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), MEMPHASYS LTD (ASX), PATRYS LIMITED (ASX), BIOTRON (ASX), Suntar Eco-City (SGX), AUSTRALIAN PRIMARY HEMP LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), REGENEUS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BIOSINO BIO-TEC (HKEx), RHINOMED LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), CRYOSITE (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --1.030
-12.47 %
10 Days --0.730
-9.17 %
20 Days --1.650
-18.58 %
Medium Term Return 3 Months --4.030
-35.79 %
6 Months --2.160
-23.00 %
1 Year -+5.060
+233.18 %
Long Term Return 2 Years -+3.060
+73.38 %
Annualised Return Annualised --
+31.67 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 2.000 - 14.400 Change From 1 Year Low +5.230 % Change From 1 Year Low (%) +261.50
Change From 1 Year High -7.170 % Change From 1 Year High (%) -49.79
2 Years Range 1.150 - 14.400 Change From 2 Years Low +6.080 % Change From 2 Years Low (%) +528.70
Change From 2 Years High -7.170 % Change From 2 Years High (%) -49.79
5 Years Range 1.150 - 18.180 Change From 5 Years Low +6.080 % Change From 5 Years Low (%) +528.70
Change From 5 Years High -10.950 % Change From 5 Years High (%) -60.23
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
12 Apr 2021 7.850 7.929 7.140 7.230 1,572,007 -
09 Apr 2021 8.180 8.262 7.850 7.950 1,221,443 -
08 Apr 2021 8.120 8.280 7.954 8.170 953,296 -
07 Apr 2021 8.210 8.360 8.070 8.070 1,034,804 -
06 Apr 2021 8.210 8.530 8.150 8.200 1,118,092 -
05 Apr 2021 8.100 8.320 7.670 8.260 1,270,950 -
01 Apr 2021 7.910 8.280 7.725 8.090 1,645,969 -
31 Mar 2021 8.270 8.460 7.760 7.800 4,039,941 -
30 Mar 2021 7.688 7.688 7.060 7.250 3,020,097 -
29 Mar 2021 8.060 8.250 7.560 7.960 3,104,596 -
26 Mar 2021 8.300 8.380 7.770 8.050 968,530 -
25 Mar 2021 7.570 8.410 7.500 8.300 1,407,960 -
24 Mar 2021 8.890 8.900 8.000 8.070 2,071,865 -
23 Mar 2021 9.360 9.590 8.570 8.700 2,032,261 -
22 Mar 2021 9.700 9.770 9.170 9.550 1,702,961 -
19 Mar 2021 8.850 9.790 8.640 9.500 3,717,345 -
18 Mar 2021 9.070 9.190 8.550 8.720 2,440,732 -
17 Mar 2021 8.570 9.390 8.410 9.110 5,026,234 -
16 Mar 2021 8.950 9.000 8.450 8.740 958,838 -
15 Mar 2021 9.340 9.390 8.750 8.880 1,447,658 -
12 Mar 2021 8.970 9.330 8.576 9.230 1,549,734 -
11 Mar 2021 8.400 9.020 7.990 9.000 1,762,641 -
Summary
Current 2 Weeks
(29 Mar 2021 to 12 Apr 2021)
8.060 8.530 7.060 7.230 18,981,195 -
Previous 2 Weeks
(15 Mar 2021 to 26 Mar 2021)
9.340 9.390 7.060 8.050 21,774,384 -
4 Weeks from
(12 Feb 2021 to 12 Mar 2021)
11.290 11.630 7.060 9.230 30,960,553 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.